Changeflow GovPing Pharma & Drug Safety Genetically Modified Clostridium Acetobutylicum...
Routine Notice Added Final

Genetically Modified Clostridium Acetobutylicum for Lignocellulosic Biomass

Favicon for changeflow.com ChangeBridge: Patent Apps - Biotech (C12N)
Published September 15th, 2023
Detected March 27th, 2026
Email

Summary

The USPTO has published a patent application (US20260085278A1) detailing genetically modified Clostridium acetobutylicum strains designed for efficient growth on lignocellulosic biomass. The application, filed by Institut National des Sciences Appliquees de Toulouse, describes overexpressing specific operons to enhance biomass conversion for producing bulk chemicals like ethanol and butanol.

What changed

This document is a USPTO patent application (US20260085278A1) concerning genetically modified Clostridium acetobutylicum strains. The core innovation involves overexpressing the cip-cel operon to improve growth on lignocellulosic biomass, enabling the production of various bulk chemicals such as ethanol, butanol, acetone, and lactic acid. The application was filed by the Institut National des Sciences Appliquees de Toulouse.

As a patent application, this document does not impose immediate regulatory obligations or compliance deadlines on regulated entities. However, it signifies potential future developments in biotechnology and chemical production. Companies operating in the pharmaceutical, biotechnology, or industrial chemical sectors may wish to monitor the progress of this patent application and related intellectual property, as it could impact future manufacturing processes and product development in areas such as biofuels and bio-based chemicals.

Source document (simplified)

← USPTO Patent Applications

GENETICALLY MODIFIED LIGNOCELLULOLYTIC CLOSTRIDIUM ACETOBUTYLICUM

Application US20260085278A1 Kind: A1 Mar 26, 2026

Assignee

Institut National des Sciences Appliquees de Toulouse

Inventors

Tom WILDING-STEELE, Quentin RAMETTE, Philippe SOUCAILLE

Abstract

The present invention relates to a genetically modified Clostridium acetobutylicum able to grow on lignocellulosic biomass, in which the cip-cel operon is overexpressed, the expression level of each gene of the cip-cel operon in the genetically modified Clostridium acetobutylicum being higher than its expression level in a corresponding non-genetically modified Clostridium acetobutylicum, as well as derivatives thereof with further modifications increasing growth on lignocellulosic biomass, and the use of these strains for the production of bulk chemicals by conversion of lignocellulose as source of carbon, such as ethanol, butanol, glycerol, 1,2-propanediol, acetone, isopropanol, isobutene, hydrogen, acetic acid and lactic acid and the like.

CPC Classifications

C12N 1/20 C12N 9/2437 C12N 9/2482 C12P 7/06 C12P 7/16 C12P 7/56 C12R 2001/145 C12Y 302/01004 C12Y 302/01008

Filing Date

2023-09-15

Application No.

19110846

View original document →

Classification

Agency
USPTO
Published
September 15th, 2023
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260085278A1

Who this affects

Applies to
Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Biotechnology Research Chemical Production
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Research & Development
Topics
Biotechnology Industrial Chemicals

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: Patent Apps - Biotech (C12N) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.